**Core tip:** Bone marrow stimulation (BMS) is a reparative procedure for osteochondral lesions of the talus, promising approximately 85% success rates in the short- and mid-term. To date, the prognostic factors for BMS are lesion size and containment of the lesion. No other factors have been shown to be universal predictors. However, the level of evidence and methodological quality of evidence for clinical studies accompanying both the lesion sizes and containment are low. Overall, 95.5% of the studies included in the analysis are level IV or level III. No level I study was identified. The methodological qualities of the included studies were not strong. In particular, the scores of "primarily evaluates outcome criteria and recruitment rates" were low.

INTRODUCTION
============

Bone marrow stimulation (BMS) is a reparative procedure for osteochondral lesions of the talus (OLT)\[[@B1]\]. The aim of this arthroscopic procedure is to stimulate mesenchymal stem cells (MSCs) to promote fibrous cartilage tissue by breaching the subchondral bone plate (SBP) using an awl or wire\[[@B1]\]. Several investigators have demonstrated good to excellent clinical outcomes in around 85% of patients, treated with BMS for OLT, for the short to medium term\[[@B2]\].

The main prognostic factor in the treatment of OLT has been regarded as the lesion size\[[@B1],[@B3],[@B4]\]. The maximum size for BMS treatment is generally accepted as less than 15 mm in diameter or 150 mm^2^ in area. Chuckpaiwong et al\[[@B4]\] found that smaller than 15 mm in diameter was the critical cut-off value to obtain a successful outcome following BMS. Choi et al\[[@B5]\] concluded that 150 mm^2^ is the critical defect area beyond clinical outcomes following BMS for OLT decreased significantly. However, a recent systematic review by Ramponi et al\[[@B6]\] showed the critical lesion size to be 107.4 mm^2^ in area and/or 10.2 mm in diameter, for BMS. Containment of the lesion has also been demonstrated as a universally accepted prognostic factor for good clinical outcomes following BMS for OLT\[[@B3],[@B7]\].

Recently, level of evidence (LOE) and methodological quality of evidence (MQOE) have been used to assess relative value of outcomes reported in the clinical studies\[[@B8]-[@B11]\]. Despite the widespread clinical use of lesion size as a cut-off value for BMS in OLT, there has been no comprehensive assessment of LOE and QOE for clinical studies accompanying both the lesion size and clinical outcomes. The same can be said for the presence or absence of containment of OLT.

The purpose of this systematic review was to clarify the LOE and MQOE of for the published literature investigating clinical outcome following BMS for OLT, with special emphasis on studies investigating lesion size and containment as predictors.

MATERIALS AND METHODS
=====================

Search strategy
---------------

A systematic literature search of the PubMed/MEDLINE and EMBASE databases was performed in March 2015 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines\[[@B12]\]. Each database was searched using the following key words, (microfracture OR microdrilling OR drilling OR drill OR bone marrow stimulation OR marrow stimulation OR BMS OR abrasion chondroplasty OR arthroscopy OR arthroscopic) AND (talus OR talar OR ankle) AND (cartilage OR osteochondritis dissecans OR chondral OR osteochondral OR transchondral OR osteochondral lesion OR OCL OR OCD).

Titles and abstracts were screened using specific inclusion and exclusion criteria. Full texts of potentially relevant studies were then reviewed. Citations and references of all articles and relevant studies were manually assessed. Studies were searched and independently assessed by two independent reviewers. Differences between reviewers were discussed together and resolved by consensus or if a persistent disagreement occurred, a senior author was consulted.

Inclusion and exclusion criteria
--------------------------------

Currently BMS is defined as microfracture, drilling, or abrasion. The inclusion criteria of the current systematic review was the following: (1) therapeutic clinical studies evaluating both lesion size of OLT and outcomes in patients who underwent BMS; (2) all patients included had more than a 24 mo follow up; (3) published in a peer-review journal; (4) published in English; and (5) full text of studies available. Exclusion criteria was the following: (1) cadaveric studies; (2) animal studies; (3) case reports; (4) review articles; (5) technique articles; (6) articles with unseparated results if more than one technique is described; (7) inadequately surgical technique description; (8) use of scaffolds; and (9) errors in reported data.

Data extraction and analysis
----------------------------

Two independent reviewers performed data extraction for each study. If any discrepancy existed, the senior author evaluated all available data and a consensus was reached. Studies that included more than one surgical procedure or a subgroup of patients with different follow-up times were included in the data for analysis\[[@B13],[@B14]\].

The primary outcome of current study was LOE and MQOE of included studies. LOE of each study was graded based on the previously published criteria\[[@B15]\]. MQOE was assessed using the Modified Coleman Methodology Score (MCMS) (Table [1](#T1){ref-type="table"})\[[@B6]\]. This score consists of 2 parts, Part A (primarily evaluates baseline study characteristics; 0-60) and Part B (primarily evaluates outcome criteria and recruitment rates; 0-40). According to Jakobsen's CMS, the score of excellent studies are between 85 to 100 points; good studies 70 to 84 points, fair studies 55 to 69 points and poor studies scored under 55 points\[[@B9]\].

###### 

Modified Coleman Methodology Score\[[@B6]\]

  **Section**                                                                                                                                                             **No. or factor**                                                                                  **Score**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -----------
  Part A: Only one score to be given for each section                                                                                                                                                                                                                        
  1 Study size - number of patients                                                                                                                                                                                                                                          
                                                                                                                                                                          \> 60                                                                                              10
                                                                                                                                                                          41-60                                                                                              7
                                                                                                                                                                          20-40                                                                                              4
                                                                                                                                                                          \< 20, not stated                                                                                  0
  2 Mean follow up (mo)                                                                                                                                                                                                                                                      
                                                                                                                                                                          \> 24                                                                                              5
                                                                                                                                                                          12-24                                                                                              2
                                                                                                                                                                          \< 12, not stated or unclear                                                                       0
  3 Number of different surgical procedures included in each reported outcome. More than one surgical technique may beassessed but separate outcomes should be reported                                                                                                      
                                                                                                                                                                          One surgical procedure                                                                             10
                                                                                                                                                                          More than one surgical procedure, but \> 90% of subjects undergoing the one procedure              7
                                                                                                                                                                          Not stated, unclear, or \< 90% of subjects undergoing the one procedure                            0
  4 Type of study                                                                                                                                                                                                                                                            
                                                                                                                                                                          Randomized controlled trial                                                                        15
                                                                                                                                                                          Prospective cohort study                                                                           10
                                                                                                                                                                          Retrospective cohort study                                                                         0
  5 Diagnostic certainty (MRI)                                                                                                                                                                                                                                               
                                                                                                                                                                          In all                                                                                             5
                                                                                                                                                                          In \> 80%                                                                                          3
                                                                                                                                                                          In \< 80%                                                                                          0
  6 Description of surgical procedure given                                                                                                                                                                                                                                  
                                                                                                                                                                          Adequate (technique stated and necessary details of that type of procedure given)                  5
                                                                                                                                                                          Fair (technique only stated without elaboration)                                                   3
                                                                                                                                                                          Inadequate, not stated, or unclear                                                                 0
  7 Description of postoperative rehabilitation                                                                                                                                                                                                                              
                                                                                                                                                                          Well described (ROM, WB and sport)                                                                 10
                                                                                                                                                                          Not adequately described (2 items between ROM and WB and sport)                                    5
                                                                                                                                                                          Protocol not reported                                                                              0
  Part B: Scores may be given for each option in each of the three sections if applicable                                                                                                                                                                                    
  1 Outcome criteria                                                                                                                                                                                                                                                         
                                                                                                                                                                          Outcome measures clearly defined                                                                   2
                                                                                                                                                                          Timing of outcome assessment clearly stated (*e.g*., at best outcome after surgery or follow-up)   2
                                                                                                                                                                          Objective, subjective and imaging criteria                                                         6
                                                                                                                                                                          2 items between objective, subjective and imaging criteria                                         4
                                                                                                                                                                          Objective or subjective or radiological criteria                                                   2
  2 Procedure for assessing outcomes                                                                                                                                                                                                                                         
                                                                                                                                                                          Subjects recruited (results not taken from surgeons files)                                         5
                                                                                                                                                                          Investigator independent of surgeon                                                                4
                                                                                                                                                                          Written assessment                                                                                 3
                                                                                                                                                                          Completion of assessment by subjects themselves with minimal investigator assistance               3
  3 Description of subject selection process                                                                                                                                                                                                                                 
                                                                                                                                                                          Selection criteria reported and unbiased                                                           5
                                                                                                                                                                          Recruitment rate reported                                                                          
                                                                                                                                                                          \> 80% or                                                                                          5
                                                                                                                                                                          \< 80%                                                                                             3
                                                                                                                                                                          Eligible subjects not included in the study satisfactorily accounted for, or 100% recruitment      5

MRI: Magnetic resonance imaging; ROM: Range of motion; WB: Weight bearing.

Statistical analysis
--------------------

The statistical analysis was performed using a commercially available contemporary statistical software package (SAS 9.3; SAS Institute, Cary, NC, United States). In CMMS, all obtained scores were adjusted to percentage (each score/total score), the adjusted scores of CMMS were compared between Part A and Part B to determine statistical significance. As a Shapiro-Wilk's *W* test showed non-normal distributed data, the Mann-Whitney *U* test was performed for this. Additionally, the adjusted score of each parameter were compared to investigate any difference using the Kruskal-Wallis test and Steel-Dwass test for data obtained without standard Gaussian distribution. A *P*-value *\<* 0.05 was considered statistically significant.

RESULTS
=======

The flow diagram is shown in Figure [1](#F1){ref-type="fig"}. After full texts articles were assessed based on the inclusion/exclusion criteria. There were 22 clinical studies included in the current systematic review\[[@B3]-[@B5],[@B7],[@B13],[@B16]-[@B32]\].

![PRISMA study selection flow diagram.](WJO-8-956-g001){#F1}

Demographics
------------

Summary of the demographic data was shown in Table [2](#T2){ref-type="table"}: 1.879 ankles were identified (931 males; 545 females)\[[@B3]-[@B5],[@B7],[@B13],[@B16]-[@B32]\]. The mean lesion area was 111.9 mm^2^ and the mean diameter was 9.5 mm. The mean follow-up was 48.5 (range 24-146) mo.

###### 

Studies included and demographic datas

  **Ref**.   **Year**   **No. of ankles**   **No. of males**   **No. of females**   **Follow -up (mo)**   **Lesion area (mm^2^)**   **Lesion diameter (mm)**   **Prognostic factors**   **LOE**   **MCMS (points)**
  ---------- ---------- ------------------- ------------------ -------------------- --------------------- ------------------------- -------------------------- ------------------------ --------- -------------------
  \[23\]     2013       50                  20                 30                   35.5                  61.7                      8.8                        Lesion size              III       58
  \[29\]     2015       15                  7                  8                    94.8                  87                                                   Lesion size              IV        50
  \[5\]      2009       120                 80                 37                   35.6                  111.7                     11.4                       Lesion size              III       56
  \[3\]      2013       399                                                         74                    111.3                                                Lesion size, contained   III       61
  \[32\]     2015       90                  68                 22                   38.3                  100                                                  Lesion size              III       67
  \[24\]     2013       298                 184                114                  52                    98.5                                                 Lesion size              III       57
  \[19\]     2012       173                 121                52                   70.3                  95.4                                                 Lesion size              III       54
  \[4\]      2008       105                 73                 32                   31.6                                            8.84                       Lesion size              IV        57
  \[16\]     2000       17                  13                 4                    84                    85.2                                                 Lesion size              III       33
  \[13\]     2006       10                  6                  4                    53                    450                                                  Lesion size              III       61
  \[18\]     2011       22                  16                 6                    32                    76                                                   Lesion size              IV        45
  \[30\]     2014       50                  28                 22                   27.1                                                                       Lesion size              III       69
  \[20\]     2012       22                  12                 10                   24                                                                         Lesion size              IV        56
  \[21\]     2012       81                  64                 17                   37.4                  100                                                  Lesion size              III       89
  \[17\]     2010       35                  27                 8                    33                    90                                                   Lesion size              IV        50
  \[31\]     2014       58                  37                 21                   35                    124                                                  Lesion size              IV        65
  \[25\]     2013       50                  30                 20                   141                                             8.8                        Lesion size              IV        62
  \[26\]     2013       38                  23                 15                   52.8                  100                                                  Lesion size              IV        52
  \[27\]     2013       50                  22                 28                   36.3                  62                                                   Lesion size              IV        66
  \[28\]     2015       41                  17                 24                   42.5                  67                                                   Lesion size              IV        56
  \[22\]     2012       25                  19                 5                    32                    110                                                  Lesion size              IV        48
  \[7\]      2011       130                 64                 66                   37.2                  84                                                   Lesion size, contained   IV        50

LOE: Level of evidence; MCMS: Modified coleman methodology score.

LOE
---

Overall, 95.5% of the studies included were level IV\[[@B4],[@B7],[@B17],[@B18],[@B20],[@B22],[@B25]-[@B29],[@B31]\] or level III\[[@B3],[@B5],[@B16],[@B19],[@B21],[@B23],[@B30],[@B32]\]. No level I studies were included in the current review. Gobbi et al\[[@B13]\], was described as LOE I in the published journal, however, this study was re-assigned as LOE II (prospective cohort study). Table [2](#T2){ref-type="table"} shows information about LOE (Table [2](#T2){ref-type="table"}).

MQOE
----

The mean MCMS was 57.5 ± 10.2 out of 100 points (range 38-89) (Table [3](#T3){ref-type="table"}). Part A was 38.1 ± 8.1 (range 22-60; percentage: 63.5%) and Part B was 19.2 ± 5.5 (range 11-29; percentage: 48.0%), respectively. The adjusted MCMS of Part A were significantly higher than that of Part B (*P* \< 0.05). In the part A, the adjusted MCMS of "Type of study" were significantly lower among all the parameters (*P* \< 0.05). With regard to Part B, "Outcome criteria" had significantly higher scores compared with the others (*P* \< 0.05). Of the 22 included studies, 14 studies (63.6%) were of fair quality\[[@B3]-[@B5],[@B13],[@B19],[@B20],[@B23]-[@B25],[@B27],[@B28],[@B30]-[@B32]\], 7 (31.7%) of poor quality\[[@B7],[@B16]-[@B18],[@B22],[@B26],[@B28]\] and only 1 (4.5%) study\[[@B21]\].

###### 

Outcome of modified Coleman methodology scores

  **Ref**.   **Part A**   **Part B**   **Total**                                             
  ---------- ------------ ------------ ----------- ----- ----- ----- ----- ----- ----- ----- ------
  \[23\]     7            5            10          0     5     3     10    8     5     5     58
  \[29\]     0            5            10          0     0     5     10    10    5     5     50
  \[5\]      10           5            10          0     5     5     10    8     5     0     58
  \[3\]      10           5            10          0     5     5     10    8     8     0     61
  \[32\]     10           5            10          0     5     5     5     6     3     8     57
  \[24\]     10           5            10          0     5     5     10    10    9     3     67
  \[18\]     10           5            10          0     5     5     10    8     3     0     56
  \[4\]      10           5            10          0     5     3     10    6     8     0     57
  \[16\]     4            5            10          0     0     3     0     8     5     3     38
  \[13\]     4            5            0           10    5     5     10    10    9     3     61
  \[18\]     4            5            10          0     5     5     5     6     5     0     45
  \[30\]     7            5            10          0     5     5     10    10    9     8     69
  \[20\]     4            2            10          0     5     3     5     10    9     8     56
  \[21\]     10           5            10          15    5     5     10    10    9     10    89
  \[17\]     4            5            10          0     5     5     5     8     5     3     50
  \[31\]     7            5            10          0     5     5     10    10    5     8     65
  \[25\]     7            5            10          0     0     3     5     10    12    5     57
  \[26\]     4            5            10          0     5     3     10    10    5     0     52
  \[27\]     7            5            10          0     5     3     10    8     8     10    66
  \[28\]     7            5            10          0     5     3     10    8     5     3     56
  \[22\]     4            2            10          0     5     5     5     8     9     0     48
  \[7\]      10           5            0           0     5     0     10    10    5     5     50
  mean       6.8          4.7          9.1         1.1   4.3   4     8.2   8.6   6.6   4     57.5
  SD         3            0.9          2.9         3.8   1.8   1.3   2.9   1.4   2.4   3.5   10.2

MRI: Magnetic resonance imaging.

DISCUSSION
==========

The aim of this systematic review is to clarify LOE and MQOE of published literature on BMS for OLT. Twenty-two studies with 1.879 patients were included, however, no level I study was identified in the study cohort. The result demonstrated that most of the studies reported the lesion sizes and the containment of the lesion were graded as low LOE. The quality of evidence in these studies demonstrated an average MCMS of 57.5 out of 100 points and only 4.5% of included studies were graded as excellent, which suggests that the methodological quality of the included studies was weak. In addition, scores of Part B (primarily evaluates outcome criteria and recruitment rates) was marked significantly lower than Part A (primarily evaluates baseline study characteristics. This systematic review has revealed that studies with low LOE and weak MQOE have supported this paradigm despite lesion size and the containment of the lesion being a common criteria value for the indication for BMS in treating OLT.

Lesion size and the containment of the lesion are accepted prognostic factors to use when making a decision in operative treatment for OLT\[[@B3],[@B7]\]. In general, lesion size with less than 15 mm in diameter or less than 150 mm^2^ are applied for BMS. It is also well known that a non-contained OLT have a worse outcome than a contained OLT\[[@B7]\]. However, this systematic review has revealed that most of these studies were of low LOE, and recently, several investigators evaluated the trend of LOE of published clinical studies in sport-related journals\[[@B33]\]. Unfortunately greater than 80% of studies in foot and ankle surgery remain to have low LOE despite increasing numbers of the LOE I and LOE II studies in the clinical sports medicine literature\[[@B9],[@B10],[@B33]\]. High-level clinical evidence can fundamentally provide adequate treatment for patients based on the principles of evidence-based medicine\[[@B34]\]. Additionally, Moher et al\[[@B35]\] described that non-blinded clinical studies without allocation concealment tended to describe an overestimated treatment effect than blinded clinical studies and well-designed blinded case control studies are required to establish prognostic factors in BMS for OLT.

The current systematic study revealed that the MQOE of the included 22 studies have been weak (Table [3](#T3){ref-type="table"})\[[@B9]\]. Of those clinical studies "Procedure for assessing outcomes" and "Description of subject selection process" in Part B (primarily evaluates outcome criteria and recruitment rates) were significantly low. These findings are consistent with the outcomes found by a recent systematic review that analyzed the outcome data following microfracture for OLT in 24 clinical studies\[[@B36]\]. The authors found that approximately half of included studies did not have a patient history or patient-reported outcome data, despite the presence of well described general demographics and study design. Additionally, clinical variables (48%) and imaging data (39%) has been the least reported in these studies. Poor methodological quality of the clinical study decreases the reliability of study's outcomes\[[@B37]\]. However, caution should be taken when interrupting the outcomes of methodological quality. The methodological deficiencies have been reported using Coleman Methodological Score for tendinopathy\[[@B8],[@B38]\], knee cartilage lesion\[[@B9]\], fracture\[[@B39]\], ligament injury\[[@B40]-[@B42]\] and OLT\[[@B43]\]. However, to our knowledge, the validity and reliability of this score for OLT is unknown. Nevertheless, we believe the outcome of the current study is important because the modification for MCMS in the current study could improve the validity and reliability of this score for OLT.

Several limitations of the current study exist mainly due to the inclusion criteria. Studies published in database other than MEDLINE and EMBASE were not included. Clinical studies not written in English were not evaluated. Nevertheless, this study does demonstrate important findings of that the LOE and QOE of published literature, on using BMS for OLT, are insufficient to produce any solid conclusion. A further limitation was that the current study focused only on the available clinical studies. As a result, the outcomes have addressed very little of the underlying mechanisms and intrinsic limitations of BMS for OLT. Currently, underlying biological aspects of cartilage regeneration has been well discussed due to low intrinsic activity of reparative cartilaginous tissue following BMS and potential ability of biological factors, although a recent systematic review has suggested a comprehensive assessment of the evidence behind the translation of basic science to the clinical practice\[[@B44],[@B45]\]. Thus, the usefulness of the outcomes from the current study depends essentially on critical appraisal of the literature on the clinical application.

In conclusion, lesion size and the containment of OLT is a commonly used prognostic parameter in the treatment of osteochondral lesion of the talus However, this systematic review has revealed that low levels of evidence and weak quality of evidence in clinical studies need to be improved before this paradigm can be fully supported.
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Terminology
-----------

BMS: Bone marrow stimulation; LOE: Level of evidence; MCMS: Modified Coleman Methodology Score; MQOE: Methodological quality of evidence; OLT: Osteochondral lesion of the talus.

Peer-review
-----------

This is a timely, objective, well-written, well-conducted systematic review of a topic relevant to the field of orthopaedics.

Conflict-of-interest statement: Kennedy JG is a consultant for Arteriocyte, Inc.; has received research support from the Ohnell Family Foundation, Mr. and Mrs. Michael J Levitt, and Arteriocyte Inc.; is a board member for the European Society of Sports Traumatology, Knee Surgery, and Arthroscopy, International Society for Cartilage Repair of the Ankle, American Orthopaedic Foot and Ankle Society Awards and Scholarships Committee, International Cartilage Repair Society finance board.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author "insert email", who will provide a permanent, citable and open-access home for the dataset.

Manuscript source: Invited manuscript

Specialty type: Orthopedics

Country of origin: Japan

Peer-review report classification

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Peer-review started: February 13, 2017

First decision: May 10, 2017

Article in press: August 16, 2017

P- Reviewer: Castagnini F, Peng BG, Xavier-Elsas P S- Editor: Ji FF L- Editor: A E- Editor: Lu YJ

[^1]: Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

    Correspondence to: Youichi Yasui, MD, 2^nd^ Department of Orthopaedic Surgery, Teikyo University School of Medicine, 1-1 Kaga, 2-Chome, Itabashi-Ku, Tokyo 173-8606, Japan. <youichi@med.teikyo-u.ac.jp>

    Telephone: +81-3-39644097 Fax: +81-3-53756864
